Do GLP-1s cause thyroid cancer? What's the boxed warning about?

The scariest-looking warning on the label deserves the most careful unpacking. Where it comes from: in 2-year rodent studies, GLP-1 agonists caused dose-dependent C-cell tumors (the cells that produce calcitonin) in rats and mice., and human thyroid physiology differs meaningfully. Regulators applied the standard precaution: a boxed warning plus contraindication for the people whose C-cells are already genetically primed. What human data shows: 15+ years of class use, multi-year cardiovascular outcome trials, and large registry analyses have not established increased medullary thyroid cancer in humans. One French database study (2022) suggested a possible association with thyroid cancers broadly, but it carried significant detection-bias concerns (people on GLP-1s get more medical attention and more neck imaging) and subsequent larger analyses, including Scandinavian registry data, have been mostly reassuring. “Mostly reassuring, surveillance continues” is the honest scientific status. The absolute rule that exists anyway: never take any GLP-1 with a personal or family history of: - Medullary thyroid carcinoma (MTC) — a rare cancer (≈1–2% of thyroid cancers) arising from C-cells; or - MEN 2 (multiple endocrine neoplasia type 2) — an inherited syndrome that makes MTC near-certain. Every legitimate intake screens for this; it’s a question worth asking older relatives about before starting, since “family history” is doing real work in that sentence. Worth knowing: routine calcitonin monitoring is not recommended for ordinary users (it generates false alarms), and the common papillary thyroid cancer is a different disease from MTC — a history of papillary cancer is a discuss-with-your-endocrinologist situation, not an automatic bar. New thyroid symptoms on therapy (a neck lump, persistent hoarseness, trouble swallowing) warrant evaluation regardless of cause.